980 related articles for article (PubMed ID: 18347167)
21. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
23. Expression profile of class I histone deacetylases in human cancer tissues.
Nakagawa M; Oda Y; Eguchi T; Aishima S; Yao T; Hosoi F; Basaki Y; Ono M; Kuwano M; Tanaka M; Tsuneyoshi M
Oncol Rep; 2007 Oct; 18(4):769-74. PubMed ID: 17786334
[TBL] [Abstract][Full Text] [Related]
24. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
25. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Waltregny D; North B; Van Mellaert F; de Leval J; Verdin E; Castronovo V
Eur J Histochem; 2004; 48(3):273-90. PubMed ID: 15590418
[TBL] [Abstract][Full Text] [Related]
26. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Hanigan CL; Van Engeland M; De Bruine AP; Wouters KA; Weijenberg MP; Eshleman JR; Herman JG
Gastroenterology; 2008 Nov; 135(5):1654-1664.e2. PubMed ID: 18834886
[TBL] [Abstract][Full Text] [Related]
27. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
28. Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells.
Ajamian F; Salminen A; Reeben M
Neurosci Lett; 2004 Jul; 365(1):64-8. PubMed ID: 15234474
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
[TBL] [Abstract][Full Text] [Related]
31. Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin.
Li X; Yin S; Meng Y; Sakr W; Sheng S
Cancer Res; 2006 Sep; 66(18):9323-9. PubMed ID: 16982778
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Ahn MY; Chung HY; Choi WS; Lee BM; Yoon S; Kim HS
Int J Oncol; 2010 Jan; 36(1):125-31. PubMed ID: 19956841
[TBL] [Abstract][Full Text] [Related]
33. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.
Horiuchi M; Morinobu A; Chin T; Sakai Y; Kurosaka M; Kumagai S
J Rheumatol; 2009 Aug; 36(8):1580-9. PubMed ID: 19531758
[TBL] [Abstract][Full Text] [Related]
34. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
35. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
36. Role for Class I histone deacetylases in multidrug resistance.
Xu Y; Jiang Z; Yin P; Li Q; Liu J
Exp Cell Res; 2012 Feb; 318(3):177-86. PubMed ID: 22154511
[TBL] [Abstract][Full Text] [Related]
37. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
38. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
39. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Ropero S; Fraga MF; Ballestar E; Hamelin R; Yamamoto H; Boix-Chornet M; Caballero R; Alaminos M; Setien F; Paz MF; Herranz M; Palacios J; Arango D; Orntoft TF; Aaltonen LA; Schwartz S; Esteller M
Nat Genet; 2006 May; 38(5):566-9. PubMed ID: 16642021
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.
Young JC; Wu S; Hansteen G; Du C; Sambucetti L; Remiszewski S; O'Farrell AM; Hill B; Lavau C; Murray LJ
Cytotherapy; 2004; 6(4):328-36. PubMed ID: 16146885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
